| Membrane transporters in drug development Nature reviews Drug discovery 9 (3), 215-236, 2010 | 3380 | 2010 |
| Adjuvant trastuzumab in HER2-positive breast cancer D Slamon, W Eiermann, N Robert, T Pienkowski, M Martin, M Press, ... New England journal of medicine 365 (14), 1273-1283, 2011 | 3045 | 2011 |
| The clonal and mutational evolution spectrum of primary triple-negative breast cancers SP Shah, A Roth, R Goya, A Oloumi, G Ha, Y Zhao, G Turashvili, J Ding, ... Nature 486 (7403), 395-399, 2012 | 2202 | 2012 |
| Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial KS Courneya, RJ Segal, JR Mackey, K Gelmon, RD Reid, ... J Clin Oncol 25 (28), 4396-4404, 2007 | 1380 | 2007 |
| Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis ML McNeely, KL Campbell, BH Rowe, TP Klassen, JR Mackey, ... Cmaj 175 (1), 34-41, 2006 | 1365 | 2006 |
| Adjuvant docetaxel for node-positive breast cancer M Martin, T Pienkowski, J Mackey, M Pawlicki, JP Guastalla, C Weaver, ... New England Journal of Medicine 352 (22), 2302-2313, 2005 | 1319 | 2005 |
| Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind … LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ... Cancer journal (Sudbury, Mass.) 7 (5), 377-387, 2001 | 1174 | 2001 |
| Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment CMM Prado, VE Baracos, LJ McCargar, T Reiman, M Mourtzakis, ... Clinical cancer research 15 (8), 2920-2926, 2009 | 1111 | 2009 |
| Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or … LS Rosen, D Gordon, M Kaminski, A Howell, A Belch, J Mackey, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 1082 | 2003 |
| Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor … B Kaufman, JR Mackey, MR Clemens, PP Bapsy, A Vaid, A Wardley, ... Journal of Clinical Oncology 27 (33), 5529-5537, 2009 | 1080 | 2009 |
| Gastric adenocarcinoma: review and considerations for future directions BJ Dicken, DL Bigam, C Cass, JR Mackey, AA Joy, SM Hamilton Annals of surgery 241 (1), 27, 2005 | 1034 | 2005 |
| Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes KS Courneya, JR Mackey, GJ Bell, LW Jones, CJ Field, AS Fairey Journal of clinical oncology 21 (9), 1660-1668, 2003 | 1004 | 2003 |
| Metabolic modulation of glioblastoma with dichloroacetate ED Michelakis, G Sutendra, P Dromparis, L Webster, A Haromy, E Niven, ... Science translational medicine 2 (31), 31ra34-31ra34, 2010 | 862 | 2010 |
| Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer ED Michelakis, L Webster, JR Mackey British journal of cancer 99 (7), 989-994, 2008 | 840 | 2008 |
| Nucleoside analogues and nucleobases in cancer treatment CM Galmarini, JR Mackey, C Dumontet The lancet oncology 3 (7), 415-424, 2002 | 742 | 2002 |
| Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines JR Mackey, RS Mani, M Selner, D Mowles, JD Young, JA Belt, ... Cancer research 58 (19), 4349-4357, 1998 | 734 | 1998 |
| Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Hugh, J Hanson, MCU Cheang, TO Nielsen, CM Perou, C Dumontet, ... Journal of clinical oncology 27 (8), 1168, 2009 | 687 | 2009 |
| Nucleoside analogues: mechanisms of drug resistance and reversal strategies CM Galmarini, JR Mackey, C Dumontet Leukemia 15 (6), 875-890, 2001 | 614 | 2001 |
| Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer JJ Farrell, H Elsaleh, M Garcia, R Lai, A Ammar, WF Regine, R Abrams, ... Gastroenterology 136 (1), 187-195, 2009 | 505 | 2009 |
| The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma J Spratlin, R Sangha, D Glubrecht, L Dabbagh, JD Young, C Dumontet, ... Clinical Cancer Research 10 (20), 6956-6961, 2004 | 502 | 2004 |
Kerry S. CourneyaUniversity of AlbertaVerified email at ualberta.ca
